Alvelestat HCl

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 535765

CAS#: 1240425-11-9 (HCl)

Description: Avelestat, also known as AZD9668 and MPH-966, is a novel, oral inhibitor of neutrophil elastase (NE), an enzyme implicated in the signs, symptoms, and disease progression in NE-driven respiratory diseases such as bronchiectasis and chronic obstructive pulmonary disease via its role in the inflammatory process, mucus overproduction, and lung tissue damage. In cell-based assays, AZD9668 inhibited plasma NE activity in zymosan-stimulated whole blood. AZD9668 has the potential to reduce lung inflammation and the associated structural and functional changes in human diseases.

Chemical Structure

img
Alvelestat HCl
CAS# 1240425-11-9 (HCl)
Instruction

Theoretical Analysis

MedKoo Cat#: 535765
Name: Alvelestat HCl
CAS#: 1240425-11-9 (HCl)
Chemical Formula: C25H23ClF3N5O4S
Exact Mass: 545.13
Molecular Weight: 582.000
Elemental Analysis: C, 51.59; H, 3.98; Cl, 6.09; F, 9.79; N, 12.03; O, 11.00; S, 5.51

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Related CAS #: 1240425-05-1 (tosylate)   848141-11-7 (free base)   1240425-11-9 (HCl)    

Synonym: Alvelestat HCl; AZD9668; AZD 9668; AZD-9668; MPH966; MPH 966; MPH-966;

IUPAC/Chemical Name: N-((5-(methanesulfonyl)pyridin-2-yl)methyl)-6-methyl-5-(1-methyl-1H-pyrazol-5-yl)-2-oxo-1-(3-(trifluoromethyl)phenyl)-1,2-dihydropyridine-3-carboxamide hydrochloride

InChi Key: QKZAYLWLQCGOLB-UHFFFAOYSA-N

InChi Code: InChI=1S/C25H22F3N5O4S.ClH/c1-15-20(22-9-10-31-32(22)2)12-21(23(34)30-13-17-7-8-19(14-29-17)38(3,36)37)24(35)33(15)18-6-4-5-16(11-18)25(26,27)28;/h4-12,14H,13H2,1-3H3,(H,30,34);1H

SMILES Code: O=C(C1=CC(C2=CC=NN2C)=C(C)N(C3=CC=CC(C(F)(F)F)=C3)C1=O)NCC4=NC=C(S(=O)(C)=O)C=C4.[H]Cl

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >3 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 582.00 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Lulla AR, Akli S, Karakas C, Caruso JA, Warma LD, Fowlkes NW, Rao X, Wang J, Hunt KK, Watowich SS, Keyomarsi K. Neutrophil elastase remodels mammary tumors to facilitate lung metastasis. Mol Cancer Ther. 2023 Oct 5. doi: 10.1158/1535-7163.MCT-23-0414. Epub ahead of print. PMID: 37796181.


2: Bhagat A, Shrestha P, Jeyabal P, Peng Z, Watowich SS, Kleinerman ES. Doxorubicin-induced cardiotoxicity is mediated by neutrophils through release of neutrophil elastase. Front Oncol. 2022 Aug 10;12:947604. doi: 10.3389/fonc.2022.947604. PMID: 36033503; PMCID: PMC9400062.


3: Sengupta S, Reddy JR, Rajesh N, Jaiswal A, Mabalirajan U, Palakodety RK, Mukherjee P, Bandyopadhyay A. Novel benzoxazinone derivative as potent human neutrophil elastase inhibitor: Potential implications in lung injury. Eur J Pharmacol. 2022 Sep 15;931:175187. doi: 10.1016/j.ejphar.2022.175187. Epub 2022 Aug 8. PMID: 35952844.


4: Otsuka R, Miyagi-Shiohira C, Kuwae K, Nishime K, Tamaki Y, Yonaha T, Sakai- Yonaha M, Yamasaki I, Shinzato M, Saitoh I, Watanabe M, Noguchi H. Pancreas Preservation with a Neutrophil Elastase Inhibitor, Alvelestat, Contributes to Improvement of Porcine Islet Isolation and Transplantation. J Clin Med. 2022 Jul 23;11(15):4290. doi: 10.3390/jcm11154290. PMID: 35893379; PMCID: PMC9330829.


5: Garciafigueroa Y, Phillips BE, Engman C, Trucco M, Giannoukakis N. Neutrophil-Associated Inflammatory Changes in the Pre-Diabetic Pancreas of Early-Age NOD Mice. Front Endocrinol (Lausanne). 2021 Mar 10;12:565981. doi: 10.3389/fendo.2021.565981. PMID: 33776903; PMCID: PMC7988208.


6: Bi Y, Zhong H, Xu K, Wu G, Han X. Regarding "Elastase inhibitor AZD9668 treatment prevented progression of experimental abdominal aortic aneurysms". J Vasc Surg. 2015 Nov;62(5):1386. doi: 10.1016/j.jvs.2015.02.056. PMID: 26506280.


7: Nordenmark LH, Taylor R, Jorup C. Feasibility of Computed Tomography in a Multicenter COPD Trial: A Study of the Effect of AZD9668 on Structural Airway Changes. Adv Ther. 2015 Jun;32(6):548-66. doi: 10.1007/s12325-015-0215-3. Epub 2015 Jun 5. PMID: 26043724.


8: Delbosc S, Rouer M, Alsac JM, Louedec L, Philippe M, Meilhac O, Whatling C, Michel JB. Elastase inhibitor AZD9668 treatment prevented progression of experimental abdominal aortic aneurysms. J Vasc Surg. 2016 Feb;63(2):486-92.e1. doi: 10.1016/j.jvs.2014.07.102. Epub 2014 Aug 28. PMID: 25175632.


9: Leidy NK, Murray LT, Jones P, Sethi S. Performance of the EXAcerbations of chronic pulmonary disease tool patient-reported outcome measure in three clinical trials of chronic obstructive pulmonary disease. Ann Am Thorac Soc. 2014 Mar;11(3):316-25. doi: 10.1513/AnnalsATS.201309-305OC. PMID: 24432712.


10: Henriksen PA. The potential of neutrophil elastase inhibitors as anti- inflammatory therapies. Curr Opin Hematol. 2014 Jan;21(1):23-8. doi: 10.1097/MOH.0000000000000001. PMID: 24241342.


11: Stockley R, De Soyza A, Gunawardena K, Perrett J, Forsman-Semb K, Entwistle N, Snell N. Phase II study of a neutrophil elastase inhibitor (AZD9668) in patients with bronchiectasis. Respir Med. 2013 Apr;107(4):524-33. doi: 10.1016/j.rmed.2012.12.009. Epub 2013 Feb 20. PMID: 23433769.


12: Gunawardena KA, Gullstrand H, Perrett J. Pharmacokinetics and safety of AZD9668, an oral neutrophil elastase inhibitor, in healthy volunteers and patients with COPD. Int J Clin Pharmacol Ther. 2013 Apr;51(4):288-304. doi: 10.5414/CP201674. PMID: 23391369.


13: Vogelmeier C, Aquino TO, O'Brien CD, Perrett J, Gunawardena KA. A randomised, placebo-controlled, dose-finding study of AZD9668, an oral inhibitor of neutrophil elastase, in patients with chronic obstructive pulmonary disease treated with tiotropium. COPD. 2012 Apr;9(2):111-20. doi: 10.3109/15412555.2011.641803. PMID: 22458939.


14: Sjö P. Neutrophil elastase inhibitors: recent advances in the development of mechanism-based and nonelectrophilic inhibitors. Future Med Chem. 2012 Apr;4(5):651-60. doi: 10.4155/fmc.12.17. PMID: 22458683.


15: Elborn JS, Perrett J, Forsman-Semb K, Marks-Konczalik J, Gunawardena K, Entwistle N. Efficacy, safety and effect on biomarkers of AZD9668 in cystic fibrosis. Eur Respir J. 2012 Oct;40(4):969-76. doi: 10.1183/09031936.00194611. Epub 2012 Jan 20. PMID: 22267768.


16: Kuna P, Jenkins M, O'Brien CD, Fahy WA. AZD9668, a neutrophil elastase inhibitor, plus ongoing budesonide/formoterol in patients with COPD. Respir Med. 2012 Apr;106(4):531-9. doi: 10.1016/j.rmed.2011.10.020. Epub 2011 Dec 23. PMID: 22197578.


17: Stevens T, Ekholm K, Gränse M, Lindahl M, Kozma V, Jungar C, Ottosson T, Falk-Håkansson H, Churg A, Wright JL, Lal H, Sanfridson A. AZD9668: pharmacological characterization of a novel oral inhibitor of neutrophil elastase. J Pharmacol Exp Ther. 2011 Oct;339(1):313-20. doi: 10.1124/jpet.111.182139. Epub 2011 Jul 26. PMID: 21791628.


18: Norman P. Crystalline form of a neutrophil elastase inhibitor, 6-methyl-5-(1 -methyl-1H-pyrazol-5-yl)-N-{[5-(methylsulfonyl)pyridin-2-yl]methyl}-2-oxo-1-[3-( trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxamide p-toluene sulfonate - is it AZD-9668?: WO-2010094964. Expert Opin Ther Pat. 2011 Feb;21(2):277-80. doi: 10.1517/13543776.2011.535813. Epub 2011 Jan 11. PMID: 21222548.


19: Seale JP. European Respiratory Society (ERS) - 20th Annual Congress. IDrugs. 2010 Nov;13(11):762-4. PMID: 21046521.